Peroxisome Proliferator-Activated Receptors: Difference between revisions

David Canner (talk | contribs)
No edit summary
David Canner (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image: 3dzy2.png|420px|left|thumb| Human PPARγ bound to RXRα and PPRE DNA strand, [[3dzy]]]]
[[Image: 3dzy2.png|420px|left|thumb| Human PPARγ bound to RXRα and PPRE DNA strand, [[3dzy]]]]
{{STRUCTURE_3dzy| right| PDB=3dzy  | SCENE=Peroxisome_Proliferator-Activated_Receptors/Ppar_opening4/1 |CAPTION= Crystal Structure of Human PPARγ, [[3dzy]] }}
{{STRUCTURE_3dzy| right| PDB=3dzy  | SCENE=Peroxisome_Proliferator-Activated_Receptors/Ppar_opening4/1 |CAPTION= Crystal Structure of Human PPARγ, [[3dzy]] }}
The [[Peroxisome Proliferator-Activated Receptors]] (PPAR) α, δ, and γ are members of the nuclear receptor family. Since their discovery in the early 90s, it has become clear that the PPARs are essential modulators of environmental and dietary stimuli, acting as transcription factors to regulate mammalian metabolism, cellular differentiation, and tumorigenesis. The PPARs are the targets of numerous pharmaceutical drugs aimed at treating [http://en.wikipedia.org/wiki/Hyperlipidemia hypolipidemia] and [http://en.wikipedia.org/wiki/Diabetes diabetes] among other diseases.<ref>PMID:15860251</ref>
The [[Peroxisome Proliferator-Activated Receptors]] (PPAR) α, δ, and γ are members of the nuclear receptor family. Since their discovery in the early 90s, it has become clear that the PPARs are essential modulators of external stimuli, acting as transcription factors to regulate mammalian metabolism, cellular differentiation, and tumorigenesis. The PPARs are the targets of numerous pharmaceutical drugs aimed at treating [http://en.wikipedia.org/wiki/Hyperlipidemia hypolipidemia] and [http://en.wikipedia.org/wiki/Diabetes diabetes] among other diseases.<ref>PMID:15860251</ref>
<br />
<br />


Line 23: Line 23:
==PPAR Structure==
==PPAR Structure==
===Ligand Binding Domain===
===Ligand Binding Domain===
The structures of the PPARs are very similar over each isotype. All PPAR isotypes have a ligand binding domain (LBD).  The LBD, which is located in the C-terminal half of the receptor, is composed of 13 α-helices and a four-stranded ß-sheet. <scene name='Peroxisome_Proliferator-Activated_Receptors/Ligand_binding_pocket/2'>The ligand binding pocket</scene>  is Y-shaped and consists of an <scene name='Peroxisome_Proliferator-Activated_Receptors/Y_shaped/4'>entrance and two pockets, Arm I and Arm II, along with a "charge-clamp"</scene>. The ligand binding pocket of PPARs is quite large in comparison to that of other nuclear receptors (about 1400 cubic angstroms) which allows the PPARs to interact with a broad range of structurally distinct ligands.<ref>PMID:9744270</ref>. Within Arm I, four polar resides are conserved over all PPAR isotypes, <scene name='Peroxisome_Proliferator-Activated_Receptors/4_conserved_residues/1'>namely Ser280, Tyr314, His440, and Tyr464</scene> in the case of PPARα. These residues are part of a hydrogen bonding network that is formed with the carboxylate group of fatty acids and other ligands upon binding.<ref>PMID:16405912</ref> The <scene name='Peroxisome_Proliferator-Activated_Receptors/Helix_h12/4'>ligand-dependent activation domain (AF-2) helix H12</scene>, whose function is to generate the receptors’ co-activator binding pocket, is located at the C-terminal end of the LBD.<ref>PMID:11027271</ref> The conserved hydrogen bonding network in <scene name='Peroxisome_Proliferator-Activated_Receptors/Helix_h12_in_place/1'>Arm I also helps hold the AF2-helix in the active conformation</scene>, promoting co-activator binding.<ref name="Zoete"/> <scene name='Peroxisome_Proliferator-Activated_Receptors/Arm_ii_hydrophobic/3'>Arm II is highly hydrophobic </scene>and is thus ideal for binding the hydrophobic tail of fatty acids via Van der Waals interactions.  
The structures of the PPARs are very similar over each isotype. All PPAR isotypes have a ligand binding domain (LBD).  The LBD, which is located in the C-terminal half of the receptor, is composed of 13 α-helices and a four-stranded ß-sheet. <scene name='Peroxisome_Proliferator-Activated_Receptors/Ligand_binding_pocket/2'>The ligand binding pocket</scene>  is Y-shaped and consists of an <scene name='Peroxisome_Proliferator-Activated_Receptors/Y_shaped/4'>entrance and two pockets, Arm I and Arm II, along with a "charge-clamp"</scene>. The ligand binding pocket of PPARs is quite large in comparison to that of other nuclear receptors (about 1400 cubic angstroms) which allows the PPARs to interact with numerous structurally distinct ligands.<ref>PMID:9744270</ref>. Within Arm I, four polar resides are conserved over all PPAR isotypes, <scene name='Peroxisome_Proliferator-Activated_Receptors/4_conserved_residues/1'>namely Ser280, Tyr314, His440, and Tyr464</scene> in the case of PPARα. These residues are part of a hydrogen bonding network that is formed with the carboxylate group of fatty acids and other ligands upon binding.<ref>PMID:16405912</ref> The <scene name='Peroxisome_Proliferator-Activated_Receptors/Helix_h12/4'>ligand-dependent activation domain (AF-2) helix H12</scene>, whose function is to generate the receptors’ co-activator binding pocket, is located at the C-terminal end of the LBD.<ref>PMID:11027271</ref> The conserved hydrogen bonding network in <scene name='Peroxisome_Proliferator-Activated_Receptors/Helix_h12_in_place/1'>Arm I also helps hold the AF2-helix in the active conformation</scene>, promoting co-activator binding.<ref name="Zoete"/> <scene name='Peroxisome_Proliferator-Activated_Receptors/Arm_ii_hydrophobic/3'>Arm II is highly hydrophobic </scene>and is thus ideal for binding the hydrophobic tail of fatty acids via Van der Waals interactions.  


Despite over 80% of the ligand binding cavity residues being conserved over all PPAR isotypes, it is the remaining 20% that creates the ligand specificity seen between isotypes. A few examples illustrate this point. In PPARδ, the cavity is significantly narrower adjacent to the AF-2 helix and Arm I. This prevents PPARδ from accommodating large headed TZDs and L-tyrosine based agonsists. In the case of PPARα, PPARα does not bind ligands with large carboxylate head groups because of <scene name='Peroxisome_Proliferator-Activated_Receptors/Tyr_314/4'> Tyrosine 314</scene> as compared to PPARγ which has a smaller equivalent residue in His323.<ref name="Zoete"/> Or in the case of binding some benzenesulfonamide derivatives, the <scene name='Peroxisome_Proliferator-Activated_Receptors/Pi_stacking/2'>pi stacking of Phe363 and the aromatic moiety</scene> in the case of PPARγ is lost in PPARα (Ile354) and PPARδ(Ile 363)<ref>PMID:16640330</ref>
Despite over 80% of the ligand binding cavity residues being conserved over all PPAR isotypes, it is the remaining 20% that creates the ligand specificity seen between isotypes. A few examples illustrate this point. In PPARδ, the cavity is significantly narrower adjacent to the AF-2 helix and Arm I. This prevents PPARδ from being able to accommode large headed TZDs and L-tyrosine based agonsists. In the case of PPARα, PPARα does not bind ligands with large carboxylate head groups because of <scene name='Peroxisome_Proliferator-Activated_Receptors/Tyr_314/4'> Tyrosine 314</scene> as compared to PPARγ which has a smaller equivalent residue in His323.<ref name="Zoete"/> Or in the case of binding some benzenesulfonamide derivatives, the <scene name='Peroxisome_Proliferator-Activated_Receptors/Pi_stacking/2'>pi stacking of Phe363 and the aromatic moiety</scene> in the case of PPARγ is lost in PPARα (Ile354) and PPARδ(Ile 363)<ref>PMID:16640330</ref>
<br />
<br />
[[Image: Binding_site.png|350px|left|thumb| Human PPARγ Ligand Binding Site with Rosiglitazone Bound. [[2prg]]]]
[[Image: Binding_site.png|350px|left|thumb| Human PPARγ Ligand Binding Site with Rosiglitazone Bound. [[2prg]]]]
Line 31: Line 31:
===AF-2 Domain: Structure and Function===
===AF-2 Domain: Structure and Function===
<applet load="2prg2.pdb" size="450" color="white" frame="true" spin="on" Scene ="Peroxisome_Proliferator-Activated_Receptors/Ppar_opening3/2" caption="Crystal Structure of Human PPAR" align="right"/>
<applet load="2prg2.pdb" size="450" color="white" frame="true" spin="on" Scene ="Peroxisome_Proliferator-Activated_Receptors/Ppar_opening3/2" caption="Crystal Structure of Human PPAR" align="right"/>
As briefly mentioned before, the AF-2 domain is essential for ligand binding and <scene name='Peroxisome_Proliferator-Activated_Receptors/Ppar_opening3/2'>PPAR</scene> function. Helix H12 of AF-2 closes on the ligand-binding site upon ligand binding, reducing conformational flexibility of the LBD and assuming a structure that is ideal for co-activator binding. Using Molecular Dynamic simulations, it has been determined that residues <scene name='Peroxisome_Proliferator-Activated_Receptors/H_bonding_network/3'>Glu324, Arg397, Arg443, and Tyr 477</scene> (in PPARγ) are involved in a hydrogen-bond network that stabilizes the AF-2 helix in the active conformation upon ligand binding.<ref>PMID:7501014</ref>
As briefly mentioned before, the AF-2 domain is essential for ligand binding and <scene name='Peroxisome_Proliferator-Activated_Receptors/Ppar_opening3/2'>PPAR</scene> function. Helix H12 of AF-2 closes on the ligand-binding site upon ligand binding, reducing conformational flexibility of the LBD and assuming a structure that is ideal for co-activator binding. Using Molecular Dynamic simulations, it has been determined that residues <scene name='Peroxisome_Proliferator-Activated_Receptors/H_bonding_network/3'>Glu324, Arg397, Arg443, and Tyr 477</scene> (in PPARγ) are involved in a hydrogen bond network that stabilizes the AF-2 helix in the active conformation upon ligand binding.<ref>PMID:7501014</ref>
<br />
<br />


Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

David Canner, Alexander Berchansky, Michal Harel, Joel L. Sussman